Amylin Pharmaceuticals Incorporated

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. The company was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The company has amassed significant research and clinical expertise in metabolic medicine including the areas of diabetes, obesity and cardiovascular disease. By "Challenging Science," Amylin challenges conventional thinking to create innovative approaches to the discovery, development and commercialization of novel therapies for metabolic diseases. Amylin's approach and dedication are rooted in the belief that they will be "Changing Lives" for millions of people - not only with the drugs currently in late-stage development, but also with their pipeline of future therapies.

Contact Details: 9373 Towne Centre Drive San Diego 92121 United States of America Tel: 619 552 2200 Fax: 619 552 2212 Email: WWW: www.amylin.com/

Recent Publications by Amylin Pharmaceuticals Incorporated:
Mechanisms of Amylin/Leptin Synergy in Rodent Models. The present studies aimed to identify mechanisms contributing to...	31st October, 2009	Amylin Pharmaceuticals (V.F.T., J.L.T., G.G., C.W., P.S.G., C.V., D.G.P.,	Endocrinology. 2009 Oct 29. DOI Direct Link
Being supermarket savvy. The present studies aimed to identify mechanisms contributing to...	31st October, 2009	Amylin Pharmaceuticals, Inc., Island Park, NY, USA.	Diabetes Self Manag. 2009 Sep-Oct;26(5):57, 59-61, 63.
Improving your diabetes care visits. The present studies aimed to identify mechanisms contributing to...	26th September, 2009	Amylin Pharmaceuticals, Inc., Lexington, Kentucky, USA.	Diabetes Self Manag. 2009 Jul-Aug;26(4):23-4, 26-8, 31.
Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. OBJECTIVE: This study assessed the pharmacokinetics, pharmacodynamics, and...	28th July, 2009	Amylin Pharmaceuticals, Inc., San Diego, California 92121, USA.	Clin Ther. 2009 Apr;31(4):806-15. DOI Direct Link
Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. AIMS: To assess treatment satisfaction and weight-related quality of life...	4th July, 2009	Amylin Pharmaceuticals Inc., San Diego, CA 92121, USA.	Diabet Med. 2009 Jul;26(7):722-8. DOI Direct Link
→View more Amylin Pharmaceuticals Incorporated research publications.

BioNews Results for Amylin Pharmaceuticals Incorporated:
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for	StockHouse USA:  Nov 1 2009 11:42PM Matching: amylin pharmaceuticals
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for	TickerTech.com:  Nov 2 2009 1:13AM Matching: amylin pharmaceuticals
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for	Stockwatch:  Nov 1 2009 11:54PM Matching: amylin pharmaceuticals
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for	Investors Business Daily:  Nov 2 2009 12:02AM Matching: amylin pharmaceuticals
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for	Business Review Albany:  Nov 2 2009 1:35AM Matching: amylin pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Amylin Pharmaceuticals Incorporated news.

Amylin Pharmaceuticals Incorporated Clinical Trials:
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Amylin Pharmaceuticals Incorporated Patents:
US Patent No.	Title
6579851	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
6936584	Mixed amylin activity compounds
6956026	Use of exendins for the reduction of food intake
6982248	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
6989366	Exendins, exendin agonists, and methods for their use
→View more Amylin Pharmaceuticals Incorporated patents.

Amylin Pharmaceuticals Incorporated (AMLN) Financial information Links from Barchart
AMLN Quote from from Barchart.com
AMLN Chart from from Barchart.com
AMLN Profile from from Barchart.com
AMLN Opinion from from Barchart.com
→View more Amylin Pharmaceuticals Incorporated finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 30 individuals from Amylin Pharmaceuticals Incorporated using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 593 times since April 2007, the link to the organisation's website has been followed 77 times

Recent Search Terms used to find this page: Synthesis biological evaluation of PYY 3-36 analogs substituted with alanine. | .

Search for more companies in San Diego

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Amylin Pharmaceuticals Incorporated